LAPTM5 and glioblastoma: As LAPTM5 was shown to sensitize CD40-positive U87MG glioblastoma cells to temozolomide and inhibited the NFκB pathway, the functional role of potential NFκB-mediated temozolomide resistance in LAPTM5 knockdown cells as well as the connection with CD40 expression was further investigated.